Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
about
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialSurvival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriersMultigene assays and molecular markers in breast cancer: systematic review of health economic analysesGenomic profiling in luminal breast cancerMolecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenPredictive and prognostic molecular markers for cancer medicineProspective Validation of a 21-Gene Expression Assay in Breast CancerTowards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancerMolecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy.Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.Biological subtypes of breast cancer: Prognostic and therapeutic implications.Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.Genomic index of sensitivity to endocrine therapy for breast cancer.Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.Genomic testing and therapies for breast cancer in clinical practice.Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic modelsPrognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer.Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea.Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.Review of the clinical studies using the 21-gene assay.Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast CancerPrediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients
P2860
Q24597456-A2DBAFD1-AEC9-4948-9B18-CE1A41B1DD3FQ24654487-89DC0E8D-3FCC-470C-A8F2-38C63EB8C478Q26825362-EAEFD15E-A34B-49E4-963D-E593E3788793Q26862681-50C7C18F-3AFA-4A98-89D3-126E5D1E69F4Q28068956-A1618A8B-424C-4BF0-B3A8-9EEBB8E05098Q28077637-55D126ED-F921-4153-86C7-255B7D42B234Q28743108-26B9D077-EB1F-4EA1-84BE-77321646385FQ29011698-8E094BDA-3BC1-418F-80EC-2567FCF6853BQ30252422-2A23A02B-44A2-4C04-ADFD-C20A58CD6C44Q31098350-9D15AFDB-A346-4331-B0C7-E0BA40C34A0CQ33472698-E8511166-8D07-47CE-BBE8-DEF5C0441237Q33692020-B17308C2-7B0C-49E8-A056-48ABB7D49626Q33751916-34766E64-00A9-41B6-B72F-BCF569B57389Q33766513-282DCB54-DAF1-4F8F-87E4-4B6718763726Q33788520-4EC25FDA-332D-4D01-ABEF-991E6A7FDEFCQ33790254-99F0B98A-3341-41E5-9EB8-824B8F42F380Q33888929-11392B9C-111E-45F1-BA76-EAFFA302F8EBQ34023695-146E5F1D-66F9-437B-9AB5-2902B728EC60Q34048120-86B050DF-614F-4FA5-A8F2-25A3B663A354Q34128373-C6A82A8B-B626-4908-9FD4-5F2A03519C62Q34171119-8BBA06CA-B41E-4C01-BD3F-C47BE7091288Q34193932-3426DEC4-900E-41B0-82DF-6640E97B42DFQ34196301-7B1F920B-B0C2-4D5E-8D64-E9D477B7B3FFQ34341066-34DC997F-27AC-40BA-9B97-FE0B464C9F69Q34638067-C14B3195-0A96-4614-84BA-A82AEF90B9D8Q34703634-BF347E4B-946A-4EA9-8BC0-178026BEF0B6Q34974164-1155217E-9EF8-4128-B802-A3BBB9163B8DQ34988987-95007CF5-F9C3-4EB4-A056-D26A9745F29FQ35034575-BB63908E-C619-4C2F-A1F8-FFC61FD76E99Q35054821-6E86B803-DA03-4CF4-9B3F-203B1D5D9764Q35146930-77A20BF1-A094-4253-B326-9BCC84275B7FQ35430076-C18B7F69-E717-46D6-A135-C72CAA3EF1EDQ35558070-C0603C19-28A6-4D3A-A23C-B4D0280F26B5Q35565641-0C826025-0C6F-49C5-B4CB-C2E188D313EEQ35584053-FD4115FF-8CDC-4645-81C4-E7110AA58554Q35683583-53F31503-27A4-48DB-B9B9-385AF55DD502Q35998425-9B103FEA-AA4C-4BA2-910E-8DD6FAF8D2F4Q36055953-2137D4F6-B58F-4B5D-B346-548CBB426A06Q36092813-1E8B4548-DC25-4F8F-B653-EEDC6483C097Q36117673-623F402F-DAA4-4AAC-910B-C9CE22134C9D
P2860
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prognostic utility of the 21-g ...... al clinicopathologic features.
@en
Prognostic utility of the 21-g ...... al clinicopathologic features.
@nl
type
label
Prognostic utility of the 21-g ...... al clinicopathologic features.
@en
Prognostic utility of the 21-g ...... al clinicopathologic features.
@nl
prefLabel
Prognostic utility of the 21-g ...... al clinicopathologic features.
@en
Prognostic utility of the 21-g ...... al clinicopathologic features.
@nl
P2093
P2860
P356
P1476
Prognostic utility of the 21-g ...... al clinicopathologic features.
@en
P2093
Barrett H Childs
Carl Yoshizawa
Edith A Perez
Frederick L Baehner
George W Sledge
Joseph A Sparano
Lawrence N Shulman
Lori J Goldstein
Nancy E Davidson
Peter M Ravdin
P2860
P304
P356
10.1200/JCO.2007.14.4501
P407
P577
2008-08-04T00:00:00Z